T regulatory cells in cancer: recent advances and therapeutic potential
- PMID: 20955112
- DOI: 10.1517/14712598.2010.529126
T regulatory cells in cancer: recent advances and therapeutic potential
Abstract
Importance of the field: The active suppression of immune responses against tumor is a major barrier to the likely success of cancer immunotherapy. There is now compelling evidence implicating T regulatory cells (Tregs) as being key players driving immune suppression. Elevated frequencies of Tregs within the peripheral circulation and tumor microenvironment of cancer patients correlate with poor prognosis and reduced survival. Understanding the mechanism of Treg elevation is critical for the development of new approaches aiming to modulate the frequency and function of Tregs to enhance the efficacy of cancer immune-based therapies.
Areas covered in this review: This review focuses on current knowledge concerning Tregs in cancer and discusses putative mechanisms which underlie the expansion of Tregs in cancer patients. Additionally, we review current strategies to deplete/suppress Treg activity, the limitations of these strategies and future perspective for improving their efficacy.
What the reader will gain: An insight of the current aspects concerning Treg subsets in cancer and an overview of recent advances in the identification of Treg-specific markers, in addition to the potential strategies to target Tregs for enhancing antitumor immunity.
Take home message: Mechanisms by which Treg functions modulate the immune response to tumors are becoming further understood. However, specific markers to tumor-specific/induced Tregs are yet to be clearly identified, which is a major limitation in optimizing strategies to specifically target Tregs in cancer. Despite this, strategies aimed at modulating Tregs in patients are providing some early encouraging results supporting the overall concept and indicating that further studies are clearly warranted.
Similar articles
-
Role of naturally arising regulatory T cells in hematopoietic cell transplantation.Biol Blood Marrow Transplant. 2006 Oct;12(10):995-1009. doi: 10.1016/j.bbmt.2006.04.009. Biol Blood Marrow Transplant. 2006. PMID: 17084366 Review.
-
Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.Cancer Res. 2010 Oct 15;70(20):7788-99. doi: 10.1158/0008-5472.CAN-10-1736. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20924102
-
Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4.J Immunol. 2010 Dec 15;185(12):7199-206. doi: 10.4049/jimmunol.1001876. Epub 2010 Nov 10. J Immunol. 2010. PMID: 21068404
-
Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy.Curr Opin Investig Drugs. 2007 Dec;8(12):1002-8. Curr Opin Investig Drugs. 2007. PMID: 18058571 Review.
-
The significance of Treg cells in defective tumor immunity.Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):181-91. doi: 10.1007/s00005-008-0018-1. Epub 2008 May 30. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18512029 Review.
Cited by
-
CD47 and CD68 expression in breast cancer is associated with tumor-infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis.J Pathol Clin Res. 2023 May;9(3):151-164. doi: 10.1002/cjp2.309. Epub 2023 Jan 4. J Pathol Clin Res. 2023. PMID: 36598153 Free PMC article.
-
CD4+CD25highCD127low/-FoxP3 + Regulatory T-Cell Population in Acute Leukemias: A Review of the Literature.J Immunol Res. 2019 Mar 3;2019:2816498. doi: 10.1155/2019/2816498. eCollection 2019. J Immunol Res. 2019. PMID: 30944830 Free PMC article. Review.
-
Clinical evaluation of systemic and local immune responses in cancer: time for integration.Cancer Immunol Immunother. 2014 Jan;63(1):45-57. doi: 10.1007/s00262-013-1480-0. Epub 2013 Oct 8. Cancer Immunol Immunother. 2014. PMID: 24100804 Free PMC article.
-
The role of regulatory T cells in cancer immunology.Immunotargets Ther. 2015 Aug 5;4:159-71. doi: 10.2147/ITT.S55415. eCollection 2015. Immunotargets Ther. 2015. PMID: 27471721 Free PMC article. Review.
-
The effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.Exp Hematol Oncol. 2014 Jan 23;3(1):3. doi: 10.1186/2162-3619-3-3. Exp Hematol Oncol. 2014. PMID: 24456704 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials